The Technical AnalystExchange: CPH Sector: Healthcare Industry: Biotechnology
Zealand Pharma A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.51% DKK633.00
America/New_York / 30 apr 2024 @ 10:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 39 420 mill |
| EPS: | -12.41 |
| P/E: | -51.01 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 62.27 mill |
| Avg Daily Volume: | 0.409 mill |
| RATING 2024-04-30 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -51.01 | sector: PE 47.95 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.26x |
| Company: PE -51.01 | industry: PE 40.56 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
DKK-305.05 (-148.19%) DKK-938.05 |
| Date: 2024-04-30 |
| Expected Trading Range (DAY) |
|---|
|
DKK 601.14 - 664.86 ( +/- 5.03%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | DKK633.00 (2.51% ) |
| Volume | 0.212 mill |
| Avg. Vol. | 0.409 mill |
| % of Avg. Vol | 51.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ZEAL.CO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ZEAL.CO
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.